Skip to main content
main-content

The independent medical news service

24-09-2021 | Oncology | News | Article

Long-term effects of COVID-19 not uncommon in cancer patients

Around one in seven people with cancer and COVID-19 report persistent symptomatic sequelae of the infection after recovery, suggest data from the OncCOVID study.

24-09-2021 | Oncology | News | Article

Combining LuPSMA with pembrolizumab ‘promising’ for mCRPC

Results of the PRINCE trial point to the potential of LuPSMA plus pembrolizumab for the treatment of metastatic castration-resistant prostate cancer with high expression of PSMA.

23-09-2021 | Oncology | News | Article

MONALEESA-2 update demonstrates ribociclib plus letrozole OS benefit

The final overall survival findings from the MONALEESA-2 trial confirm the long-term benefits of combining ribociclib with first-line letrozole for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer.

22-09-2021 | Oncology | News | Article

CASPIAN update cements durvalumab–chemo as standard of care for extensive-stage SCLC

The overall survival advantage offered by the use of durvalumab alongside first-line chemotherapy in people with extensive-stage small-cell lung cancer is sustained over time, suggests the 3-year follow-up of the CASPIAN study.

22-09-2021 | Oncology | News | Article

Adequate response to COVID-19 vaccine in people receiving anticancer therapy

Administration of two doses of the Moderna vaccine against COVID-19 elicits an adequate immune response in most, but not all, patients with a solid tumor treated with chemotherapy, immunotherapy, or both, indicate findings.

21-09-2021 | Oncology | News | Article

Drug-free interval feasible in metastatic RCC

Incorporating a drug-free interval into first-line treatment for metastatic clear cell renal cell carcinoma may not be detrimental to patient survival or quality of life, suggest STAR trial data presented at the ESMO Congress 2021.

21-09-2021 | Oncology | News | Article

Extended letrozole may improve long-term survival of early-stage breast cancer

Extending adjuvant aromatase inhibitor therapy with letrozole to 5 years improves survival among women with hormone receptor-positive breast cancer who have already received 2 to 3 years of tamoxifen, shows the phase 3 GIM4 trial.

20-09-2021 | Oncology | News | Article

STAMPEDE heralds ‘practice change’ for high-risk nonmetastatic prostate cancer

Supplementing androgen deprivation therapy with 2 years of an abiraterone acetate-based regimen significantly boosts the survival of men with high-risk nonmetastatic prostate cancer, show STAMPEDE results.

20-09-2021 | Oncology | News | Article

PEACE-1: Upfront triplet therapy gives OS advantage to men with mCSPC

The addition of abiraterone acetate to standard therapy with docetaxel plus androgen deprivation therapy significantly improves the overall survival of patients with de novo metastatic castration-sensitive prostate cancer, report the PEACE-1 investigators.

19-09-2021 | Oncology | News | Article

Trastuzumab deruxtecan supported for pretreated HER2-mutant NSCLC

Trastuzumab deruxtecan achieves durable responses in individuals who have received prior treatment for metastatic non-small-cell lung cancer harboring HER2 mutations, suggests the DESTINY-Lung01 trial.

19-09-2021 | Oncology | News | Article

ARCHES reports enzalutamide OS benefit in men with mCSPC

The final analysis of the ARCHES trial has demonstrated a significant overall survival boost with the addition of enzalutamide instead of placebo to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting.

18-09-2021 | Oncology | News | Article

Trastuzumab deruxtecan shows ‘unprecedented efficacy’ in DESTINY-Breast03

Previously treated patients with HER2-positive metastatic breast cancer derive a significant progression-free survival benefit from trastuzumab deruxtecan relative to trastuzumab emtansine, find the DESTINY-Breast03 investigators.

18-09-2021 | Oncology | News | Article

COAST points to potential of durvalumab combinations in stage III NSCLC

Individuals with unresectable locally advanced non-small-cell lung cancer and no progression after chemoradiotherapy could benefit from the addition of the CD73 inhibitor oleclumab or the NKG2A-targeted agent monalizumab to consolidation durvalumab, suggest phase 2 results.

17-09-2021 | Oncology | News | Article

Cetrelimab–erdafitinib duo shows promise in advanced urothelial carcinoma

Adding the novel anti-PD-1 agent cetrelimab to the pan-FGFR inhibitor erdafitinib doubles the response rate in cisplatin-ineligible patients with untreated locally advanced or metastatic urothelial cancer and FGFR alterations, indicate trial data.

17-09-2021 | Oncology | News | Article

BrighTNess update confirms benefit of adding carboplatin to neoadjuvant chemo in TNBC

Adding carboplatin to neoadjuvant paclitaxel is sufficient to boost the outcomes of patients with triple-negative breast cancer, with no further improvement from the addition of veliparib to the dual regimen, confirms a follow-up analysis of the BrighTNess trial.

17-09-2021 | Oncology | News | Article

Updated CheckMate 743 data support dual checkpoint blockade in mesothelioma

Extended follow-up of the phase 3 CheckMate 743 trial shows the continued overall survival benefit of first-line treatment with nivolumab plus ipilimumab over chemotherapy in patients with unresectable malignant pleural mesothelioma.

17-09-2021 | Oncology | News | Article

FDA approves mobocertinib for advanced NSCLC with EGFR exon 20 insertions

Click through to read more about this approval

16-09-2021 | Oncology | News | Article

Residual cancer burden may predict treatment efficacy in breast cancer

Residual cancer burden offers prognostic information after neoadjuvant chemotherapy across breast cancer subtypes and treatments, show data from I-SPY2.

15-09-2021 | Oncology | News | Article

No overall survival benefit with first-line bevacizumab–erlotinib in EGFR-mutant NSCLC

The addition of bevacizumab to erlotinib does not improve the overall survival of treatment-naïve patients with advanced non-small-cell lung cancer harboring an activating EGFR mutation, NEJ026 study data show.

14-09-2021 | Oncology | News | Article

No new safety signals for neoadjuvant, maintenance atezolizumab in mesothelioma

Neoadjuvant atezolizumab meets researcher-defined safety criteria for use in combination with cisplatin plus pemetrexed and then as postsurgical maintenance therapy for people with resectable malignant pleural mesothelioma.